Peptide Aggregation and Self-Association
Peptides can associate into reversible oligomers, insoluble particles, fibrils, or amorphous aggregates. Aggregation is governed by sequence, concentration, pH, ionic strength, temperature, agitation, surfaces, and formulation.
Driving forces
- hydrophobic interactions
- hydrogen bonding
- electrostatic attraction
- aromatic stacking
- disulfide exchange
- backbone alignment
- reduced solvation
Concentration effects
Aggregation often becomes more favorable as peptide concentration increases. However, dilution can increase adsorption losses, so formulation development must balance both risks.
Interfaces
Air-liquid, ice-liquid, glass-liquid, and plastic-liquid interfaces can promote structural rearrangement or adsorption. Shaking, foaming, pumping, and repeated transfer increase interfacial exposure.
Detection methods
Potential methods include:
- size-exclusion chromatography
- analytical ultracentrifugation
- dynamic light scattering
- light obscuration
- microscopy
- turbidity
- field-flow fractionation
- mass spectrometry under suitable conditions
- spectroscopy
Each method detects a different size range or property.
Reversible versus irreversible association
Some oligomers dissociate after dilution or changes in pH or ionic strength. Others become kinetically trapped or form insoluble particles. Sample preparation can therefore change what the method observes.
Frequently asked questions
Does a clear solution mean no aggregates?
No. Subvisible particles and soluble oligomers may be present.
Can filtration solve aggregation?
Filtration may remove particles but does not correct the underlying instability and can reduce recovery.
Is size-exclusion chromatography sufficient?
It is useful but may miss weakly associated species that dissociate on-column.
Can lyophilization cause aggregation?
Yes. Freezing, concentration during ice formation, drying stress, and reconstitution can all influence association.
Key takeaways
Aggregation spans a broad range of sizes and reversibility. No single method captures every form, so orthogonal analysis and controlled sample handling are essential.
References
- ICH Q1A(R2). Stability Testing of New Drug Substances and Products.
- Manning MC, et al. Stability of protein pharmaceuticals. Pharm Res. 1989.
- Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999.
- FDA. Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry.
- ICH Q2(R2). Validation of Analytical Procedures.
- ICH Q14. Analytical Procedure Development.
TSMS Labs educational disclaimer: For laboratory research and educational purposes only. Not for human consumption. This content is not medical, clinical, or regulatory advice.